Sinclair DIRECT (Dermatology Investigational Research Education and Clinical Trials)

Condition(s): Cancer, Healthy Volunteers, Metabolic and Endocrine, Musculoskeletal, Other, Public Health, Skin

ADDRESS: Level 3, 2 Wellington Parade, East Melbourne, VIctoria, Australia
POSTAL ADDRESS: Level 3, 2 Wellington Parade, East Melbourne, VIctoria, Australia
PHONE: +61396542426
WEBSITE: Visit Website

MAIN CONTACT

Name: Dr Carol Robinson
Role: Study Coordinator
Phone: 61488965426
Email: carol.robinson@sinclairdermatology.com.au

OTHER CONTACTS

Name: Professor Rod Sinclair
Role: Investigator
Phone: +61396542426
Email: rodney.sinclair@sinclairdermatology.com.au

Sinclair Dermatology. Sinclair Dermatology is Victoria’s largest dermatology clinic with 8 Dermatologists and a Plastic Surgeon and 5 sites across Victoria in Melbourne’s North, East, South and Centre as well as Gippsland.
We have 2 Principal investigators, 2 trial co-ordinators and 4 Associate investigators. We are a private site, but are affiliated with the Epworth Hospital. We can use either Bellbury or the Epworth hospital HREC. We have an onsite pharmacy and pathology collection centre. We have access to a research laboratory with centrifuge and minus 70 freezers. We do phase 1, Phase II, Phase III and Phase IV studies.

Therapeutic Areas: Sinclair Direct have experience in Biologic trials in psoriasis, atopic dermatitis, urticaria, pemphigus and alopecia as well as vaccine trials and pharmaceutical trials in skin.

CURRENT CLINICAL TRIALS

A Phase I/IIa Study of the Efficacy and Safety of ASN-002 in Adult Patients with Low-Risk Nodular Basal Cell Carcinoma

JOBS (CURRENT OPEN POSITIONS)

No current jobs

SITE EXPERIENCE

Protocol title: Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
Registry: ClinicalTrials.gov
Registry #: NCT02647086
Link to registry: See Registry

Protocol title: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)
Registry: ClinicalTrials.gov
Registry #: NCT02207231
Link to registry: See Registry

Protocol title: Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Registry: ClinicalTrials.gov
Registry #: NCT02134210
Link to registry: See Registry

Protocol title: Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis (PSOR-003)
Registry: ClinicalTrials.gov
Registry #: NCT00606450
Link to registry: See Registry

Protocol title: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
Registry: ClinicalTrials.gov
Registry #: NCT01729754
Link to registry: See Registry

Protocol title: Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE)
Registry: ClinicalTrials.gov
Registry #: NCT01358578
Link to registry: See Registry

Protocol title: Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT01365455
Link to registry: See Registry

Protocol title: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)
Registry: ClinicalTrials.gov
Registry #: NCT01806597
Link to registry: See Registry

Want access to more Site details?

Sponsors and CROs looking to choose Sites for their next clinical trial are encouraged to sign up to AustralianClinicalTrials.com. In doing so, you will get free access to any and all Site Selection Packages, ready for you to download. Curated by Sites themselves, all the information you need to know for selection is presented in an easy to read format, saving you time and money. Create an account, and become a part of the fastest growing clinical trials community today!